Lapsed and revoked end an EUA differently
An Emergency Use Authorization depends on a declaration underneath it — and the declaration can lapse on its own calendar, ending every EUA built on it, without FDA ever revoking a single one for anything the product did.
By Connor Griggs — Regulatory & Quality Strategist
“The emergency is over” is a sentence about public health. It is not, on its own, a sentence about whether a specific product’s Emergency Use Authorization is still valid. Section 564 of the FD&C Act (21 U.S.C. 360bbb-3) builds every EUA out of two separate instruments, each running on its own clock, and only one of the two endings is a finding about the product.
Two instruments, one dependency
An EUA does not stand on its own. It depends on a prior declaration — issued by the HHS Secretary under Section 564(b) — that circumstances exist justifying emergency use: an actual or significant potential military emergency, a domestic emergency, a public health emergency affecting national security, or a Homeland Security material-threat determination under the Public Health Service Act. FDA cannot authorize an individual product’s emergency use without one of those four declarations already in place underneath it, and the statute ties the two together explicitly.
An authorization under this section shall be effective until the earlier of the termination of the declaration under subsection (b) of this section or a revocation under subsection (g) of this section.
Take the declaration away, and every authorization resting on it ends at the same moment — automatically, without FDA making any separate finding about any one of the products it covers.
The declaration runs on a calendar the product never sees
A Section 564(b) declaration is not open-ended. It terminates at the earlier of two events: the Secretary determining that the circumstances behind it have ceased, or the declaration reaching the end of the one-year period beginning on the date it was made. Nothing in that clock asks whether an authorized product is still safe, still effective, or still needed — it asks only whether the emergency is still the emergency the Secretary found. HHS renews a declaration that is still doing real work; the public health emergency declaration behind the COVID-19 pandemic’s device EUAs was renewed on exactly that basis, more than once. A declaration can also simply run out unrenewed. Either way, every EUA resting on it ends with it, for a reason that has nothing to do with the product’s own record.
Revocation asks the other question
Revocation runs on a different test entirely. Section 564(c) sets the standard an EUA has to meet in the first place: FDA must conclude, based on the totality of the scientific evidence, that it is reasonable to believe the product may be effective for its authorized use, that its known and potential benefits outweigh its known and potential risks, and that no adequate, approved, and available alternative exists. Section 564(g) lets FDA revise or revoke an authorization the moment that standard stops being met — a specific, product-level finding, not a calendar event.
FDA’s 2022 revocation of the emergency use of oral chloroquine phosphate and hydroxychloroquine sulfate for COVID-19 is the model case. The agency concluded it was no longer reasonable to believe the products were effective for the authorized use, or that their benefits still outweighed their risks, and revoked the authorization under Section 564(g)(2) on that finding.
Both get published; only one explains the product
Neither ending happens quietly. Section 564(h)(1) requires FDA to publish a Federal Register notice — with an explanation — of every authorization, and of every termination or revocation. A declaration’s own termination gets advance Federal Register notice too. The record does not go dark either way; what differs is what the explanation is actually explaining. A termination notice explains why the emergency no longer meets the declaration’s own test. A revocation notice explains why the product no longer meets Section 564(c)’s. Reading only the headline — terminated, or revoked — without checking which of the two documents you are holding tells you an EUA ended, and nothing about why.
The practice
Before treating any EUA’s end as evidence about a product, check which document produced it. A declaration’s termination or lapse says the emergency footing changed; it is not a comment on the product FDA authorized under it. A revocation says FDA re-ran Section 564(c)’s benefit-risk test and the product failed it. FDA Radar’s Federal Register source reads guidance availability notices, classification rules, proposed and final rules, and comment deadlines on a continuous, dated cadence — a Section 564 notice is a fifth category the same federalregister.gov feed carries that isn’t named among them, so an EUA’s status still needs a manual check against FDA’s own listing. This is regulatory intelligence and method, describing how two statutory endings differ — never regulatory advice about what a specific product’s authorization status means for a specific submission or supply decision.
Primary sources
- 21 U.S.C. § 360bbb-3 — Authorization for medical products for use in emergencies
- FDA — Emergency Use Authorization
- FDA guidance — Emergency Use Authorization of Medical Products and Related Authorities
- Federal Register — Revocation of Emergency Use of a Drug During the COVID-19 Pandemic; Availability
- FDA Radar — what we monitor and how often
Regulatory intelligence, not regulatory advice. This post describes method and published FDA records as of its date; decisions about a specific device belong with your regulatory professional.